Literature DB >> 20180870

Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure.

A Hutchinson1, C Brand, L Irving, C Roberts, P Thompson, D Campbell.   

Abstract

BACKGROUND: In 2003, chronic obstructive pulmonary disease (COPD) accounted for 46% of the burden of chronic respiratory disease in the Australian community. In the 65-74-year-old age group, COPD was the sixth leading cause of disability for men and the seventh for women. AIMS: To measure the influence of disease severity, COPD phenotype and comorbidities on acute health service utilization and direct acute care costs in patients admitted with COPD.
METHODS: Prospective cohort study of 80 patients admitted to the Royal Melbourne Hospital in 2001-2002 for an exacerbation of COPD. Patients were followed for 12 months and data were collected on acute care utilization. Direct hospital costs were derived using Transition II, an activity-based costing system. Individual patient costs were then modelled to ascertain which patient factors influenced total direct hospital costs.
RESULTS: Direct costs were calculated for 225 episodes of care, the median cost per admission was AU$3124 (interquartile range $1393 to $5045). The median direct cost of acute care management per patient per year was AU$7273 (interquartile range $3957 to $14 448). In a multivariate analysis using linear regression modelling, factors predictive of higher annual costs were increasing age (P= 0.041), use of domiciliary oxygen (P= 0.008) and the presence of chronic heart failure (P= 0.006).
CONCLUSION: This model has identified a number of patient factors that predict higher acute care costs and awareness of these can be used for service planning to meet the needs of patients admitted with COPD.

Entities:  

Mesh:

Year:  2010        PMID: 20180870     DOI: 10.1111/j.1445-5994.2010.02195.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  13 in total

Review 1.  Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.

Authors:  Kunal Srivastava; Deepika Thakur; Sheetal Sharma; Yogesh Suresh Punekar
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

Review 2.  Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease.

Authors:  Charlotta Karner; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 3.  The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Authors:  Charlotta Karner; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 4.  Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.

Authors:  Charlotta Karner; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

5.  Classification of Exacerbation Frequency in the COPDGene Cohort Using Deep Learning With Deep Belief Networks.

Authors:  Jun Ying; Joyita Dutta; Ning Guo; Chenhui Hu; Dan Zhou; Arkadiusz Sitek; Quanzheng Li
Journal:  IEEE J Biomed Health Inform       Date:  2016-12-21       Impact factor: 5.772

Review 6.  Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Authors:  Jimmy Chong; Charlotta Karner; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 7.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

Review 8.  Tiotropium versus placebo for chronic obstructive pulmonary disease.

Authors:  Charlotta Karner; Jimmy Chong; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2014-07-21

Review 9.  Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.

Authors:  Mario Malerba; Matteo Nardin; Giuseppe Santini; Nadia Mores; Alessandro Radaeli; Paolo Montuschi
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

10.  Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Authors:  Kai Michael Beeh; Anne-Marie Kirsten; Ana-Maria Tanase; Alexia Richard; Weihua Cao; Bettina Hederer; Jutta Beier; Oliver Kornmann; Richard N van Zyl-Smit
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.